Exhibition Report | Haibu PharmaceuticΩ©♠al Debuts at the 2024 6th CMC-China✘ Expo
Classification:
Company News
Release time:
2024-08-19
Beijing Haibu Pharmaceutical Tec ₽±hnology Co., Ltd. (referred to€γ♦ as 'Haibu Pharmaceuti♣$cal') was established in ✘∑€"2005 and is a high-tech enterp£₹×±rise focused on 'chemic ®¶↑al drug R&D' as its core capa≠₹§☆bility. It has a researcλ₽↔h center in Beijing,± $ an API and formulation pilot validatio↕¥n center, and a GMP industrialπφ production base.It mainly engages in API and formulatioγ£n CRO services, MAH formulationσ≈ R&D and licensing, API-rσ★elated registration and commercial$Ω™ supply, innovative a÷& nd improved drug R&D applications ★≠, etc., having been aw↔∞®♠arded the title of 'To±Ω≈ p 20 Chinese Pharmaceutical ≈¥ R&D Companies' for s≠ ♠everal consecutive years. It has b∑♥✘een recognized as a 'Beijing Science ¥¥ and Technology Research De§£velopment Institution', 'Nationa•™l High-tech Enterprise', 'Beijing Yi∑•zhuang Enterprise In<£novation Center'.
Haibu Pharmaceutical has rich experienc®σ✘☆e in the R&D transfer production, ∞♣registration applicationε≤ φ of various dosage forms<¥♦→ such as chemical APIs,¥₽ oral solids, liquid formulations≤, sterile injections, external preparat≤€₹←ions, etc. The R&D p₽ roducts cover multiple th©♠erapeutic areas includingδ¥ anti-tumor, anti-depressi€♦<¥on, anti-epilepsy, anti-an☆÷≠xiety, cardiovascular &aπ>&£mp; cerebrovascular diseas™→←es, digestive system disorders, respλ™iratory system issues.



